drug
insulin
updated 5mo agoby Shanghai Jiao Tong University
community read0 votes
🐶 often sniffed alongside
top 8- tagRecall90 co-mentions · 24 sources
- tagApproval86 co-mentions · 43 sources
- tagType 2 Diabetes47 co-mentions · 12 sources
- drugAFREZZA28 co-mentions · 14 sources
- drugSOLIQUA 100/3324 co-mentions · 12 sources
- company$TNDMTANDEM DIABETES CARE INC21 co-mentions · 7 sources
- tagType 1 Diabetes20 co-mentions · 2 sources
- druginsulin degludec LA16 co-mentions · 16 sources
all catalysts(2)
phase 0 trial completion · 1
Trials studying insulin
- phase4A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India
- N/AClinical Evaluation of the Medtronic Implantable Insulin Pump System (MIIPS 2020) in Adult Subjects With Type 1 Diabetes (CIP347)
- —A Research Study to Examine Blood Sugar Control, Treatment Satisfaction and Adherence in People With Type 2 Diabetes After Switching From Daily Basal Insulin to Once-weekly Insulin Icodec
- —Research Study to Examine Blood Sugar Control, Treatment Satisfaction and Adherence in People With Type 2 Diabetes After Switching From Daily Basal Insulin to Once-weekly Insulin Icodec
- phase1A Study to Test How Insulin NNC0471-0119 H Works in the Body in Participants With Type 1 Diabetes When Given by an Insulin Pump
- —A Research Study to See How Insulin Icodec Helps People With Type 1 Diabetes Control Their Blood Sugar
- phase3AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
- N/AAutomated Insulin Delivery Versus Usual Insulin Treatment Modality Before and During Pregnancy in Women With Type 1 Diabetes
News(10)
- Nova Biomedical® Announces Global Medical Device Correction for StatStrip® Glucose Hospital MeterWALTHAM, Mass., October 5, 2026 – Nova Biomedical initiated a global Medical Device Correction on July 24, 2026, for the StatStrip® Glucose Hospital Meter System due to a software issue that may ca…fda_recalls · 5d ago
- Kailera, Hengrui’s GLP-1/GIP candidate delivers weight, menstrual benefits to women with PMOSKailera Therapeutics and Hengrui Pharma’s weekly injection showed benefits beyond weight loss in a mid-stage trial, leading to more regular menstrual cycles in patients with polyendocrine metabolic…biospace · 8d ago
- Zealand's stock slides as Boehringer-partnered obesity drug underwhelms again in phase 3A phase 3 trial of Boehringer Ingelheim’s survodutide in people with obesity and Type 2 diabetes has met its co-primary endpoints. Yet, with the readout echoing earlier data that underwhelmed analy…fiercebiotech · 9d ago
- Lilly raises diabetes weight-loss bar with amylin-Zepbound comboEli Lilly announced its amylin-Zepbound combination eloraTZP resulted in 23.3% weight loss in adults with type 2 diabetes and obesity or overweight, topping its own triple-G drug candidate retatrut…fiercebiotech · 10d ago
- STAT+: Overton won’t get a vote before midtermsHealth department nominees await Senate votes, and we map out what the elections mean for healthy policy.stat · 11d ago
- Roche cuts muscle-sparing obesity drug after mid-stage disappointmentRoche’s anti-myostatin therapy emugrobart is unlikely to elicit meaningful weight loss, according to an interim mid-stage analysis, prompting the pharma to return the asset rights to its subsidiary…biospace · 11d ago
- STAT+: AstraZeneca invests $2 billion in Summit TherapeuticsAstraZeneca is teaming up with Summit Therapeutics to test its PD-1/VEGF bispecific ivonescimab alongside AstraZeneca’s antibody-drug conjugates.stat · 11d ago
- STAT+: UniQure’s gene therapy continues to slow Huntington’s progression after four yearsUniQure's gene therapy continues to slow Huntington's progression after four years. But the magnitude of the benefit waned compared to a similar analysis from a year ago.stat · 11d ago
- STAT+: Drug pricing, Medicaid, and research funding: The key policy issues at stake in the midtermsBig shifts in health care policy could emerge depending on who wins the midterms, affecting hospitals and pharma companies.stat · 11d ago
- Novo agrees $2.6B deal for preclinical GLP-1/GIP drug from in-demand HengruiNovo’s ongoing efforts to rejuvenate its pipeline have seen the Big Pharma turn to one of the most in-demand drug developers in China.fiercebiotech · 12d ago
Data sources
last refreshed 11m ago
Found something off?
comments(0)
5-min edit window · permanent after that